PNOC Study in Childhood Brain Cancer Enrols First Patient
- Written by PR Newswire Asia - Daily Bulletin Au RSS
SYDNEY, Nov. 11, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that PNOC022 (NCT05009992), a multi-drug phase II study in DIPG and diffuse midline gliomas, has been initiated at the University of California, San Francisco, with the first patient...
Read more: PNOC Study in Childhood Brain Cancer Enrols First Patient